Newsfeeds - Spark Newswire

1 minute read

$100 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth This Much

Today, 3:55 AM

CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 13.5% on an annualized basis producing an average annual return of 25.08%. Currently, CRISPR Therapeutics has a market capitalization of $4.02 billion.

CRSP

48 minute read

Stocks That Hit 52-Week Lows On Thursday

By Benzinga Insights

Today, 3:55 AM

During Thursday, 849 stocks hit new 52-week lows.

AADI

1 minute read

$1000 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth This Much

By Benzinga Insights

Today, 3:55 AM

CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 14.85% on an annualized basis producing an average annual return of 28.2%. Currently, CRISPR Therapeutics has a market capitalization of $4.51 billion.

CRSP

1 minute read

Here’s How Much $1000 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth Today

By Benzinga Insights

Today, 3:55 AM

CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 12.09% on an annualized basis producing an average annual return of 26.02%. Currently, CRISPR Therapeutics has a market capitalization of $5.12 billion.

CRSP

1 minute read

Citigroup Maintains Neutral on CRISPR Therapeutics, Lowers Price Target to $64

By Benzinga Newsdesk

Today, 3:55 AM

Citigroup analyst Yigal Nochomovitz maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Neutral and lowers the price target from $90 to $64.

CRSP

2 minute read

What Are Whales Doing With CRISPR Therapeutics

By Benzinga Insights

Today, 3:55 AM

A whale with a lot of money to spend has taken a noticeably bullish stance on CRISPR Therapeutics. Looking at options history for CRISPR Therapeutics (NASDAQ:CRSP) we detected 15 strange trades.

CRSP

1 minute read

SVB Leerink Maintains Outperform on CRISPR Therapeutics, Lowers Price Target to $120

By Benzinga Newsdesk

Today, 3:55 AM

SVB Leerink analyst Rick Bienkowski maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Outperform and lowers the price target from $126 to $120.

CRSP

2 minute read

CRISPR Therapeutics and ViaCyte, Inc. Announce First Patient Dosed In Phase 1 Clinical Trial Of Novel Gene-Edited Cell Replacement Therapy For Treatment Of Type 1 Diabetes (T1D)

By Bill Haddad

Today, 3:55 AM

CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, and ViaCyte, Inc., a clinical-stage regenerative medicine company developing

CRSP